These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 30931360)

  • 1. Management of Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitor Therapy: a Minireview of Current Clinical Guidelines.
    Trinh S; Le A; Gowani S; La-Beck NM
    Asia Pac J Oncol Nurs; 2019; 6(2):154-160. PubMed ID: 30931360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Updates and emerging trends in the management of immune-related adverse events associated with immune checkpoint inhibitor therapy.
    La-Beck NM; Owoso J
    Asia Pac J Oncol Nurs; 2024 Sep; 11(9):100549. PubMed ID: 39234578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Advanced Non-small Cell Lung Cancer: A Network Meta-Analysis of Randomized Clinical Trials.
    Zhang W; Gu J; Bian C; Huang G
    Front Pharmacol; 2021; 12():686876. PubMed ID: 34759817
    [No Abstract]   [Full Text] [Related]  

  • 4. Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients.
    Song P; Zhang D; Cui X; Zhang L
    Thorac Cancer; 2020 Sep; 11(9):2406-2430. PubMed ID: 32643323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint inhibitor-associated ophthalmic adverse events: current understanding of its mechanisms, diagnosis, and management.
    Zhou YW; Xu Q; Wang Y; Xia RL; Liu JY; Ma XL
    Int J Ophthalmol; 2022; 15(4):646-656. PubMed ID: 35450191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
    Weber JS; Postow M; Lao CD; Schadendorf D
    Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulmonary Toxicities Associated With the Use of Immune Checkpoint Inhibitors: An Update From the Immuno-Oncology Subgroup of the Neutropenia, Infection & Myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer.
    Rapoport BL; Shannon VR; Cooksley T; Johnson DB; Anderson L; Blidner AG; Tintinger GR; Anderson R
    Front Pharmacol; 2021; 12():743582. PubMed ID: 34675810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance.
    Bhardwaj M; Chiu MN; Pilkhwal Sah S
    Cutan Ocul Toxicol; 2022 Mar; 41(1):73-90. PubMed ID: 35107396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of the Adverse Effects of Immune Checkpoint Inhibitors.
    Morgado M; Plácido A; Morgado S; Roque F
    Vaccines (Basel); 2020 Oct; 8(4):. PubMed ID: 33019641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
    Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
    Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.
    Chen C; Wu B; Zhang C; Xu T
    Int Immunopharmacol; 2021 Jun; 95():107498. PubMed ID: 33725634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text].
    Muntyanu A; Netchiporouk E; Gerstein W; Gniadecki R; Litvinov IV
    J Cutan Med Surg; 2021; 25(1):59-76. PubMed ID: 32746624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence.
    Vaddepally RK; Kharel P; Pandey R; Garje R; Chandra AB
    Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32245016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Review of Immune-Mediated Adverse Events in Melanoma.
    Kennedy LB; Salama AKS
    Oncol Ther; 2019 Dec; 7(2):101-120. PubMed ID: 32699983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities.
    Villadolid J; Amin A
    Transl Lung Cancer Res; 2015 Oct; 4(5):560-75. PubMed ID: 26629425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis and Management of Hematological Adverse Events Induced by Immune Checkpoint Inhibitors: A Systematic Review.
    Omar NE; El-Fass KA; Abushouk AI; Elbaghdady N; Barakat AEM; Noreldin AE; Johar D; Yassin M; Hamad A; Elazzazy S; Dermime S
    Front Immunol; 2020; 11():1354. PubMed ID: 33193289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of immune checkpoint inhibitor-related adverse events: A review of case reports.
    Si X; Song P; Ni J; Di M; He C; Zhang L; Liu X; Li Y; Wang H; Guo X; Zhou J; Duan L; Yang X; Wang M; Zhang L
    Thorac Cancer; 2020 Mar; 11(3):498-504. PubMed ID: 31970923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review.
    Friedman CF; Proverbs-Singh TA; Postow MA
    JAMA Oncol; 2016 Oct; 2(10):1346-1353. PubMed ID: 27367787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
    Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
    BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.